JP2014510788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510788A5 JP2014510788A5 JP2014505231A JP2014505231A JP2014510788A5 JP 2014510788 A5 JP2014510788 A5 JP 2014510788A5 JP 2014505231 A JP2014505231 A JP 2014505231A JP 2014505231 A JP2014505231 A JP 2014505231A JP 2014510788 A5 JP2014510788 A5 JP 2014510788A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- unsaturated
- ocf
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 224
- 150000001875 compounds Chemical class 0.000 claims description 168
- 229910052739 hydrogen Inorganic materials 0.000 claims description 129
- 239000001257 hydrogen Substances 0.000 claims description 129
- 229920006395 saturated elastomer Polymers 0.000 claims description 121
- 150000003839 salts Chemical class 0.000 claims description 82
- 150000002148 esters Chemical class 0.000 claims description 81
- 239000000651 prodrug Substances 0.000 claims description 81
- 229940002612 prodrug Drugs 0.000 claims description 81
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 69
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 68
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 60
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 60
- 150000002431 hydrogen Chemical group 0.000 claims description 60
- 229910052757 nitrogen Inorganic materials 0.000 claims description 60
- 229910052760 oxygen Inorganic materials 0.000 claims description 60
- 239000001301 oxygen Substances 0.000 claims description 60
- 125000005842 heteroatom Chemical group 0.000 claims description 59
- 229910052717 sulfur Inorganic materials 0.000 claims description 59
- 239000011593 sulfur Substances 0.000 claims description 59
- 229910052731 fluorine Inorganic materials 0.000 claims description 52
- 229910052801 chlorine Inorganic materials 0.000 claims description 50
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 150000002367 halogens Chemical class 0.000 claims description 50
- 229910052794 bromium Inorganic materials 0.000 claims description 48
- 229910052740 iodine Inorganic materials 0.000 claims description 48
- 125000001424 substituent group Chemical group 0.000 claims description 44
- 208000015181 infectious disease Diseases 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 30
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 230000000813 microbial effect Effects 0.000 claims description 26
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 18
- 125000001188 haloalkyl group Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 150000001721 carbon Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 244000005700 microbiome Species 0.000 claims description 14
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 241000606125 Bacteroides Species 0.000 claims description 10
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 8
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 8
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 102000006635 beta-lactamase Human genes 0.000 claims description 8
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229960003085 meticillin Drugs 0.000 claims description 8
- 241000194033 Enterococcus Species 0.000 claims description 7
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 7
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 7
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- 241000588767 Proteus vulgaris Species 0.000 claims description 6
- 108010059993 Vancomycin Proteins 0.000 claims description 6
- 125000003725 azepanyl group Chemical group 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 108010068385 carbapenemase Proteins 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 6
- 125000003566 oxetanyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 229940007042 proteus vulgaris Drugs 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims description 6
- 229960003165 vancomycin Drugs 0.000 claims description 6
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 6
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims description 6
- 241000588919 Citrobacter freundii Species 0.000 claims description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 5
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 4
- 241000606219 Bacteroides uniformis Species 0.000 claims description 4
- 241000193468 Clostridium perfringens Species 0.000 claims description 4
- 241000588914 Enterobacter Species 0.000 claims description 4
- 241000605909 Fusobacterium Species 0.000 claims description 4
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 4
- 241000588749 Klebsiella oxytoca Species 0.000 claims description 4
- 241000588655 Moraxella catarrhalis Species 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- 241000191992 Peptostreptococcus Species 0.000 claims description 4
- 241001135211 Porphyromonas asaccharolytica Species 0.000 claims description 4
- 241000588770 Proteus mirabilis Species 0.000 claims description 4
- 241000588768 Providencia Species 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229940049954 penicillin Drugs 0.000 claims description 4
- 206010040872 skin infection Diseases 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000005942 tetrahydropyridyl group Chemical group 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 241000606124 Bacteroides fragilis Species 0.000 claims description 3
- 241000588923 Citrobacter Species 0.000 claims description 3
- 241001657508 Eggerthella lenta Species 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 241000186561 [Clostridium] clostridioforme Species 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 241000589291 Acinetobacter Species 0.000 claims description 2
- 206010060968 Arthritis infective Diseases 0.000 claims description 2
- 208000031729 Bacteremia Diseases 0.000 claims description 2
- 241000606215 Bacteroides vulgatus Species 0.000 claims description 2
- 241000588697 Enterobacter cloacae Species 0.000 claims description 2
- 241000606766 Haemophilus parainfluenzae Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000588915 Klebsiella aerogenes Species 0.000 claims description 2
- 241000589248 Legionella Species 0.000 claims description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 claims description 2
- 241000588771 Morganella <proteobacterium> Species 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 241000606210 Parabacteroides distasonis Species 0.000 claims description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 2
- 206010035148 Plague Diseases 0.000 claims description 2
- 206010035737 Pneumonia viral Diseases 0.000 claims description 2
- 241000605861 Prevotella Species 0.000 claims description 2
- 241001135215 Prevotella bivia Species 0.000 claims description 2
- 241000588778 Providencia stuartii Species 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 241000607715 Serratia marcescens Species 0.000 claims description 2
- 206010058028 Shunt infection Diseases 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 claims description 2
- 241000193985 Streptococcus agalactiae Species 0.000 claims description 2
- 241000194008 Streptococcus anginosus Species 0.000 claims description 2
- 241001291896 Streptococcus constellatus Species 0.000 claims description 2
- 208000034784 Tularaemia Diseases 0.000 claims description 2
- 230000037006 agalactosis Effects 0.000 claims description 2
- 208000022338 anthrax infection Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 210000003555 cloaca Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 229940092559 enterobacter aerogenes Drugs 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 2
- 229960003907 linezolid Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004197 pelvis Anatomy 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 claims description 2
- 208000013223 septicemia Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 208000019206 urinary tract infection Diseases 0.000 claims description 2
- 230000002792 vascular Effects 0.000 claims description 2
- 208000009421 viral pneumonia Diseases 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 241000588917 Citrobacter koseri Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000186394 Eubacterium Species 0.000 claims 1
- 241001169527 Morganella sp. (in: Fungi) Species 0.000 claims 1
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 1
- 241000588777 Providencia rettgeri Species 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 229940032049 enterococcus faecalis Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- -1 t- butyl Chemical group 0.000 claims 1
- 208000016255 tiredness Diseases 0.000 claims 1
- 230000003867 tiredness Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
- 0 *C(*)(C(*)(*)C(*)(*)N)C(*)(*)c(ccc(*)c1C(NC2=N3)=CC2=CN(c2c(*)c(*)c(C(*)(*)NCCCNC(N)=N)c(I)c2*)C3=O)c1O* Chemical compound *C(*)(C(*)(*)C(*)(*)N)C(*)(*)c(ccc(*)c1C(NC2=N3)=CC2=CN(c2c(*)c(*)c(C(*)(*)NCCCNC(N)=N)c(I)c2*)C3=O)c1O* 0.000 description 9
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161476138P | 2011-04-15 | 2011-04-15 | |
| US61/476,138 | 2011-04-15 | ||
| US201161535118P | 2011-09-15 | 2011-09-15 | |
| US61/535,118 | 2011-09-15 | ||
| US201261610363P | 2012-03-13 | 2012-03-13 | |
| US61/610,363 | 2012-03-13 | ||
| PCT/US2012/032994 WO2012173689A2 (en) | 2011-04-15 | 2012-04-11 | Antimicrobial compounds and methods of making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018068456A Division JP2018115206A (ja) | 2011-04-15 | 2018-03-30 | 抗菌化合物ならびにそれを作製および使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510788A JP2014510788A (ja) | 2014-05-01 |
| JP2014510788A5 true JP2014510788A5 (enExample) | 2015-05-28 |
| JP6317669B2 JP6317669B2 (ja) | 2018-04-25 |
Family
ID=47357660
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505231A Active JP6317669B2 (ja) | 2011-04-15 | 2012-04-11 | 抗菌化合物ならびにそれを作製および使用する方法 |
| JP2018068456A Pending JP2018115206A (ja) | 2011-04-15 | 2018-03-30 | 抗菌化合物ならびにそれを作製および使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018068456A Pending JP2018115206A (ja) | 2011-04-15 | 2018-03-30 | 抗菌化合物ならびにそれを作製および使用する方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9221827B2 (enExample) |
| EP (2) | EP2697229B1 (enExample) |
| JP (2) | JP6317669B2 (enExample) |
| KR (1) | KR20140065378A (enExample) |
| CN (2) | CN109053695A (enExample) |
| AR (1) | AR088781A1 (enExample) |
| AU (3) | AU2012271228B2 (enExample) |
| BR (1) | BR112013026410A2 (enExample) |
| CA (1) | CA2833169A1 (enExample) |
| DK (1) | DK2697229T3 (enExample) |
| EA (1) | EA201391536A1 (enExample) |
| ES (1) | ES2665988T3 (enExample) |
| HU (1) | HUE036755T2 (enExample) |
| IL (1) | IL228845A0 (enExample) |
| MX (1) | MX357903B (enExample) |
| MY (1) | MY173518A (enExample) |
| PH (1) | PH12013502135A1 (enExample) |
| PT (1) | PT2697229T (enExample) |
| SG (2) | SG194489A1 (enExample) |
| TW (2) | TWI656123B (enExample) |
| WO (1) | WO2012173689A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0739738Y2 (ja) | 1989-10-03 | 1995-09-13 | 三菱農機株式会社 | 機体転倒防止装置 |
| US9216979B2 (en) | 2009-10-16 | 2015-12-22 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| AU2010306646B2 (en) | 2009-10-16 | 2016-09-01 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| PH12012500734A1 (en) | 2009-10-16 | 2012-11-26 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| JP6317669B2 (ja) | 2011-04-15 | 2018-04-25 | メリンタ セラピューティクス インコーポレイテッド | 抗菌化合物ならびにそれを作製および使用する方法 |
| US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
| US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
| EP2970219B1 (en) | 2013-03-15 | 2019-02-27 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
| AU2014315045A1 (en) * | 2013-09-09 | 2016-03-24 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| EP3039025A4 (en) | 2013-09-09 | 2017-05-31 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| EP3230259B1 (en) | 2014-12-08 | 2024-04-03 | The Research Foundation for The State University of New York | Anti-fungals targeting the synthesis of fungal shingolipids |
| KR20180015114A (ko) * | 2015-03-11 | 2018-02-12 | 멜린타 테라퓨틱스, 인크. | 항미생물 화합물 및 이의 제조 및 사용 방법 |
| CN105669519B (zh) * | 2016-01-04 | 2018-01-05 | 北方民族大学 | 吲哚类化合物、制备方法及其作为抗耐药菌药物的应用 |
| EP3452479A1 (en) * | 2016-05-06 | 2019-03-13 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| WO2017193023A1 (en) * | 2016-05-06 | 2017-11-09 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| CN109790165A (zh) | 2016-05-06 | 2019-05-21 | 梅林塔治疗学股份有限公司 | 抗微生物剂及其制备和使用方法 |
| WO2018232298A1 (en) | 2017-06-16 | 2018-12-20 | The Research Foundation For The State University Of New York | Anti-fungals compounds targeting the synthesis of fungal sphingolipids |
| WO2018236692A1 (en) | 2017-06-19 | 2018-12-27 | Duffy Erin M | Antimicrobials and methods of making and using same |
| WO2019164880A1 (en) * | 2018-02-21 | 2019-08-29 | Duffy Erin M | Antimicrobials and methods of making and using same |
| US12152031B2 (en) | 2018-06-06 | 2024-11-26 | BioVersys AG | Biodefense agents |
| WO2019234509A2 (en) | 2018-06-06 | 2019-12-12 | BioVersys AG | Aminomethylamidine and methylamidine antimicrobial compounds |
| US20240239800A1 (en) * | 2018-12-07 | 2024-07-18 | BioVersys AG | Pyrrolo[2,3-d]pyrimidin-2-one antimicrobial compounds |
| AU2020384885A1 (en) * | 2019-11-13 | 2022-06-09 | Curza Global, Llc | Antimicrobial compounds and methods |
| CN111254091B (zh) * | 2020-01-20 | 2022-04-19 | 浙江工业大学 | 一种嗜麦芽窄食单胞菌gyh及其在降解氯代烃类污染物中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2873340B2 (ja) | 1988-04-29 | 1999-03-24 | 武田薬品工業株式会社 | 抗生物質ｔａｎ―１０５７，その製造法および用途 |
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
| CA2297055A1 (en) | 1997-08-07 | 1999-02-18 | Research Corporation Technologies, Inc. | Antibiotic for methicillin resistant bacteria |
| DE19838998A1 (de) | 1998-08-27 | 2000-03-09 | Bayer Ag | Neue Naturstoffderivate |
| EP1113008A1 (en) | 1999-12-29 | 2001-07-04 | Pfizer Products Inc. | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents |
| KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
| DE10061542A1 (de) | 2000-12-11 | 2002-06-13 | Bayer Ag | Alkanoylamino-pyrimidine |
| DE10061541A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Arylamino-Dihydropyrimidinone |
| DE10061537A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | beta-Alanin-Derivate |
| DE10061538A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Ureido-Dihydropyrimidinone |
| US6900215B2 (en) | 2000-12-15 | 2005-05-31 | Merck Sharp & Dohme Ltd. | Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| DE10133277A1 (de) | 2001-07-09 | 2003-01-23 | Bayer Ag | ß-Alanin-Derivate |
| DE10141271A1 (de) | 2001-08-23 | 2003-03-06 | Bayer Ag | Neue Tetrahydro-1,3,5-triazin-2-on-Derivate und ihre Verwendung |
| DE10208256A1 (de) | 2002-02-26 | 2003-09-04 | Bayer Ag | Piperidinouracile |
| AU2003225705A1 (en) | 2003-03-07 | 2004-09-30 | Ribapharm Inc. | Cytidine analogs and methods of use |
| TW200509938A (en) * | 2003-08-26 | 2005-03-16 | Teijin Pharma Ltd | Pyrrolopyrimidine thion derivatives |
| NZ544187A (en) | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| AU2007270276A1 (en) * | 2006-07-03 | 2008-01-10 | Sk Chemicals Co., Ltd. | Salts of pyrrolopyrimidinone derivatives and process for preparing the same |
| KR20080003599A (ko) | 2006-07-03 | 2008-01-08 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법 |
| US20100112561A1 (en) | 2006-08-25 | 2010-05-06 | Stefan Lutz | Fluorescent nucleoside analogues |
| ES2362805T3 (es) * | 2006-09-07 | 2011-07-13 | Industrial Research Limited | Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas. |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| WO2008154642A2 (en) | 2007-06-12 | 2008-12-18 | Achaogen, Inc. | Antibacterial agents |
| GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
| KR20090098710A (ko) | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
| US20100190747A1 (en) | 2009-01-27 | 2010-07-29 | Hideo Suzuki | Fused ring compound and use thereof |
| EP2669290A1 (en) * | 2009-03-02 | 2013-12-04 | Alnylam Pharmaceuticals Inc. | Nucleic Acid Chemical Modifications |
| ES2620177T3 (es) | 2009-10-15 | 2017-06-27 | Guerbet | Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas |
| AU2010306646B2 (en) * | 2009-10-16 | 2016-09-01 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| SG10201406634VA (en) * | 2009-10-16 | 2014-11-27 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| JP6317669B2 (ja) | 2011-04-15 | 2018-04-25 | メリンタ セラピューティクス インコーポレイテッド | 抗菌化合物ならびにそれを作製および使用する方法 |
-
2012
- 2012-04-11 JP JP2014505231A patent/JP6317669B2/ja active Active
- 2012-04-11 CA CA2833169A patent/CA2833169A1/en not_active Abandoned
- 2012-04-11 ES ES12799934.0T patent/ES2665988T3/es active Active
- 2012-04-11 PH PH1/2013/502135A patent/PH12013502135A1/en unknown
- 2012-04-11 SG SG2013076575A patent/SG194489A1/en unknown
- 2012-04-11 BR BR112013026410A patent/BR112013026410A2/pt not_active Application Discontinuation
- 2012-04-11 MX MX2013012015A patent/MX357903B/es active IP Right Grant
- 2012-04-11 AU AU2012271228A patent/AU2012271228B2/en not_active Ceased
- 2012-04-11 CN CN201810630324.1A patent/CN109053695A/zh active Pending
- 2012-04-11 DK DK12799934.0T patent/DK2697229T3/en active
- 2012-04-11 US US14/112,027 patent/US9221827B2/en active Active
- 2012-04-11 MY MYPI2013003732A patent/MY173518A/en unknown
- 2012-04-11 HU HUE12799934A patent/HUE036755T2/hu unknown
- 2012-04-11 WO PCT/US2012/032994 patent/WO2012173689A2/en not_active Ceased
- 2012-04-11 KR KR1020137030273A patent/KR20140065378A/ko not_active Ceased
- 2012-04-11 EP EP12799934.0A patent/EP2697229B1/en active Active
- 2012-04-11 PT PT127999340T patent/PT2697229T/pt unknown
- 2012-04-11 SG SG10201603027QA patent/SG10201603027QA/en unknown
- 2012-04-11 EP EP18162332.3A patent/EP3404028A1/en not_active Withdrawn
- 2012-04-11 CN CN201280029215.5A patent/CN103958514B/zh not_active Expired - Fee Related
- 2012-04-11 EA EA201391536A patent/EA201391536A1/ru unknown
- 2012-04-13 TW TW101113195A patent/TWI656123B/zh not_active IP Right Cessation
- 2012-04-13 TW TW107106234A patent/TW201843154A/zh unknown
- 2012-04-16 AR ARP120101303A patent/AR088781A1/es unknown
-
2013
- 2013-10-13 IL IL228845A patent/IL228845A0/en unknown
-
2015
- 2015-11-04 US US14/932,508 patent/US20190322668A1/en not_active Abandoned
-
2017
- 2017-07-12 AU AU2017204803A patent/AU2017204803A1/en not_active Abandoned
-
2018
- 2018-03-30 JP JP2018068456A patent/JP2018115206A/ja active Pending
-
2019
- 2019-07-02 AU AU2019204745A patent/AU2019204745A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510788A5 (enExample) | ||
| JP2013508297A5 (enExample) | ||
| JP2013508299A5 (enExample) | ||
| JP2013508298A5 (enExample) | ||
| JP2016121171A5 (enExample) | ||
| CA2433197A1 (en) | Gyrase inhibitors and uses thereof | |
| ES2542431T3 (es) | Monobactamas | |
| IL165715A (en) | 2-ureido-6-heteroaryl-3h-benzimidazole-4-carboxylic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| EP2814483A2 (en) | Methods of treating bacterial infections | |
| RU2512396C2 (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| JP2017509646A (ja) | 抗真菌化合物の調製方法 | |
| HK1199249A1 (en) | Oxazolidinone antibiotics containing fused ring | |
| JP2017514790A (ja) | 抗真菌化合物の調製方法 | |
| RU2011105388A (ru) | Оксазолопиримидины как агонисты рецептора edg-1 | |
| JP2007500707A5 (enExample) | ||
| JP2011526286A5 (enExample) | ||
| KR102237887B1 (ko) | 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법 | |
| KR20140054396A (ko) | 바이아릴 헤테로고리로 치환된 옥사졸리디논 항균제 | |
| CN107400126A (zh) | 新型噁唑烷酮类化合物及其制备方法和在医学上的应用 | |
| JP2008543964A5 (enExample) | ||
| EP4342484A1 (en) | Pharmaceutical composition comprising macrocosine compound and method for preparing macrocosine compound | |
| JP2008546825A5 (enExample) | ||
| Kim et al. | In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone. | |
| WO2025147685A1 (en) | Triterpenoid antifungals for use in the treatment of mucormycosis | |
| JP2024106366A (ja) | 抗黄色ブドウ球菌剤及び化合物の使用 |